Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 170 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chronic Obstructive Pulmonary Disease Severe Clear all
Completed Phase 1Phase 2 Interventional

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

NCT03790332
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Ibrutinib
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
1 Year to 21 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
20
States / cities
Duarte, California • San Diego, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Jul 23, 2026, 10:48 PM EDT
Terminated Phase 3 Interventional Results available

Simvastatin Therapy for Moderate and Severe COPD

NCT01061671
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
simvastatin, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
40 Years to 80 Years
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
35
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2018 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 2 Interventional Results available

Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)

NCT02796651
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease - COPD
Interventions
Formoterol fumarate (6 μg), Formoterol furmarate (20 μg), Placebo for formoterol fumarate, Formoterol fumarate (12 μg), Formoterol fumarate (40 μg)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
20
States / cities
Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 3 Interventional Results available

Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01154127
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
NVA237, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2012 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Not applicable Interventional Results available

An Intervention to Improve Function in Severe Cardiopulmonary Illness

NCT00467298
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Heart Failure
Interventions
Exercise adherence, Self-management- prevention of illness, Self-management of illness
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
45 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 1, 2018 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 2 Interventional

PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00683722
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema, Chronic Bronchitis
Interventions
Prochymal™, Placebo
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Los Angeles, California • Torrance, California • Charlotte, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 3 Interventional Results available

The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT00620022
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 300 μg, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Torrance, California • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 16, 2011 · Synced Jul 23, 2026, 10:48 PM EDT
Not listed Phase 3 Interventional

EASE Trial: Exhale Airway Stents for Emphysema

NCT00391612
View directory record Official record
Conditions
Emphysema
Interventions
Exhale® Drug-Eluting Stent, Sham control
Device
Lead sponsor
Broncus Technologies
Industry
Eligibility
35 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
26
States / cities
Phoenix, Arizona • Fresno, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 3 Interventional Results available

A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis

NCT01276639
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550, Placebo/CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
32
States / cities
Birmingham, Alabama • Irvine, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Jul 23, 2026, 10:48 PM EDT
Recruiting Not applicable Interventional

Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS

NCT07108166
View directory record Official record
Conditions
COPD, Smoking, Tobacco Use
Interventions
Cigarette, THS
Other
Lead sponsor
Philip Morris Products S.A.
Industry
Eligibility
40 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
46
States / cities
Clearwater, Florida • Coral Gables, Florida • Davie, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 2 Interventional Results available

PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

NCT01566773
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT001 MDI, Tiotropium Bromide, PT001 Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
10
States / cities
Fullerton, California • Clearwater, Florida • Panama City, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

NCT04542057
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Ensifentrine, Placebo
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
77
States / cities
Alabaster, Alabama • Andalusia, Alabama • Jasper, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 3 Interventional Results available

A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00622635
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 300 μg, Placebo to indacaterol, Salmeterol 50 μg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
7
States / cities
Normal, Illinois • Shawnee Mission, Kansas • Lafayette, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT01089127
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
69
States / cities
Florence, Alabama • Jasper, Alabama • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Jul 23, 2026, 10:48 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

NCT06878261
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
68
States / cities
Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Participants With Moderate to Severe Obstructive Sleep Apnea, and in Adult and Elderly Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT04647383
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Pulmonary Disease, Chronic Obstructive, Respiration Disorders
Interventions
Placebo, Lemborexant 10 mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
11
States / cities
Glendale, Arizona • San Diego, California • Brandon, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Jul 23, 2026, 10:48 PM EDT
Active, not recruiting Not applicable Interventional

RejuvenAir® System Trial for COPD With Chronic Bronchitis

NCT03893370
View directory record Official record
Conditions
Chronic Bronchitis
Interventions
RejuvenAir System, Sham Control Procedure
Device
Lead sponsor
CSA Medical, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
26
States / cities
Scottsdale, Arizona • Mountain View, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2024 · Synced Jul 23, 2026, 10:48 PM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control

NCT01043601
View directory record Official record
Conditions
COPD
Interventions
Inhaled PT005, Inhaled Placebo, Formoterol Fumarate 12 µg (Foradil Aerolizer)
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Not applicable Interventional Results available

In-home Evaluation of a Noninvasive Open Ventilation System in Patients With Severe Respiratory Insufficiency

NCT01347931
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Airflow Obstruction, Chronic, Chronic Obstructive Airway Disease, Chronic Obstructive Lung Disease
Interventions
NIOV System, Standard Oxygen Cannula
Device
Lead sponsor
Breathe Technologies, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 2 Interventional Results available

PT003 MDI Cardiovascular Safety Study

NCT01349803
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT005 MDI, PT001 MDI, PT003 MDI, Formoterol Fumarate 12 μg (Foradil® Aerolizer®)
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
Glendale, Arizona • Fullerton, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 2 Interventional

Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide

NCT01543919
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
PH-797804, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 80 Years
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
45
States / cities
Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2014 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Not applicable Interventional

Use of Wii Home Computer in Patients With Chronic Obstructive Pulmonary Disease: Effects on Quality of Life

NCT01539421
View directory record Official record
Conditions
COPD
Interventions
Use of Home exercise computer program
Behavioral
Lead sponsor
Trinity Health Of New England
Other
Eligibility
40 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 2 Interventional Results available

PT003 MDI Dose Confirmation Study

NCT01349816
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT003, PT001, PT005
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
13
States / cities
Rancho Mirage, California • Colorado Springs, Colorado • Waterbury, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

NCT01709214
View directory record Official record
Conditions
Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Interventions
Cebranopadol (GRT6005) Low-Dose Range, Cebranopadol (GRT6005) High-Dose Range, Placebo, Oxycodone CR
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
83
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Jul 23, 2026, 10:48 PM EDT